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The detection of the JAK2 V617F mutation has become a key
component in the diagnostic procedure in patients suspected of
a chronic myeloproliferative disorder. The proportion of patients
with polycythemia vera (PV) harboring the mutation is at least
97% with sensitive PCR-based methods, whereas approximately
half of the patients with essential thrombocythemia (ET) and
primary myelofibrosis (PMF) are JAK2 V617F-positive.1,2 The
source used for DNA or RNA mutation analysis is peripheral
blood (PB), mostly granulocytes. It is evident that the JAK2
V617F mutation is detectable also in bone marrow (BM)
specimens.3,4 A growing body of evidence suggests that the
JAK2 V617F allele burden and in particular the state of
homozygosity in PV has an impact on disease phenotype as
regards the degree of elevated hemoglobin levels, pruritus4–6
leukocytosis,4,5 microvascular symptoms,4 thrombocytosis,
thrombosis, splenomegaly and propensity to develop secondary
myelofibrosis.5 Furthermore, the JAK2 V617F allele burden in
PB increases from ET over PV to primary myelofibrosis (PMF),
which might reflect a biological continuum, the phenotypic
presentation in part influenced by the mutant allele burden.
However, the size of the JAK2 V617F allele burden varies
considerably within a given phenotype, that is in PV ranging
from a few percent to almost 100%.4,7 No clear correlation
between disease duration or the need for cytoreductive
treatment and JAK2 V617F allele burden has been reported.4,5
Despite a relatively low allele burden, patients may have a
proliferative disease with a need for cytoreductive treatment as
well as frequent phlebotomies in patients with PV. Thus, one
could speculate that the JAK2 V617F allele burden measured in
PB does not reflect the true size of the JAK2 V617F mutant
clone, which may account for a larger proportion in the BM.
To date, a correlation between the JAK2 V617F allele burden
in PB and BM has not been reported. In the present study, we
provide evidence of a highly significant correlation between the
JAK2 V617F allele burden as assessed by quantitative real-time
PCR (qPCR), measured in unfractionized white blood cells
(WBCs) from PB and BM biopsies.
In the period from January to March 2007, 11 consecutive
patients (ET¼ 2, PV¼ 8, PMF¼ 1) (Table 1) were enrolled in the
study, which was conducted according to the Helsinki
Declaration and the guidelines of the Danish Regional Science
Ethics Committee. Twenty milliliters of ethylenediaminetetraa-
cetic acid-anticoagulated blood was collected together with a
BM biopsy and aspirate. Nine patients (patient nos. 1–8 and 11)
were newly diagnosed, whereas two patients (patient nos. 10–11)
were followed for a period of 12 and 60 months respectively
before collection of the BM and PB used in this study. Patient
no. 9 had a 60 months history of discrete bilinear cytopenia
(thrombocytopenia and leucopenia) and slight myelodysplastic
BM changes. Both the cytopenia and dysplastic changes
resolved and a more proliferative phenotype evolved and
accordingly a new BM biopsy was performed. Patient nos. 10
was diagnosed with slight anemia and BM features suggesting
PMF 12 months before the sample collection for the present
study. None of these two patients received cytoreductive
therapy before this study. Unfractionized WBCs from PB were
used as the DNA source. Paraffin-embedded BM trephines were
fixated in formaldehyde for 24 h, followed by decalcification
with formic acid exposition for 6 h. DNA extraction was
performed using a MagnaPure robot (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s protocol.
qPCR was performed as described previously.8 Briefly, two real-
time qPCRs were performed in parallel with a common forward
primer and a Taqman probe and only differed in the use of a
reverse primer specific for the JAK2 wild type and the V617F
mutated DNA respectively. The JAK2 V617F proportion was
calculated from standard curves and end point determination
from limiting dilution series of JAK2 wild-type donor DNA and
the homozygous JAK2 cell line HEL. All qPCRs were performed
in triplicates.
The 11 patients had a median JAK2 V617F% of 54 and 53 in
PB and BM, respectively (range: PB, 21–92%; BM, 30–85%).
Table 1 Patient number, diagnosis and the JAK2 V617F% in PB,
BM biopsy and aspirate
Patient. no. JAK2 V617F%
Diagnosis PB BM biopsy BM aspirate
1 PV 91 82 89
2 ET 21 42 ()
3 PV 32 30 ()
4 PV 54 56 58
5 PV 49 52 50
6 ET 41 36 ()
7 PV 76 77 79
8 PV 32 39 38
9 PV 57 38 40
10 PMF 92 85 ()
11 PV 59 50 48
Abbreviations: BM, bone marrow; ET, essential thrombocythemia;
PB, peripheral blood; PMF, primary myelofibrosis; PV, polycythemia vera.
Figure 1 Correlation between JAK2 V617F% in PB unfractionized
WBC and BM. Spearman’s r¼ 0.76 (P¼ 0.007). The line represents the
fitted regression line with a regression coefficient of 1.09 (95%
confidence interval: 0.6932764–1.483659, Po0.0001). BM, bone
marrow; PB, peripheral blood.
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The highest JAK2 V617F percentage was recorded in the patient
with PMF, which is in line with previous data (unpublished).
A highly significant correlation was found between levels of
JAK2 V617F percentages in PB and BM, (Spearman’s r¼ 0.76;
P¼ 0.007) (Figure 1). Furthermore, in the seven patients from
whom both a BM biopsy and a representative BM aspirate were
available, the JAK2 V617F proportion determined in the two
different BM samples was equivalent (Spearman’s r¼ 0.96;
P¼ 0.0005). The amount of extracted DNA, reflected by the
cycle threshold (Ct) value, was higher in the BM aspirates
compared to the BM biopsies (data not shown). This finding
might be explained by degradation of DNA caused by the formic
acid decalcification procedure. It is evident that some patients,
in particular with ET, have rather small JAK2 V617F allele
burdens below 10%.4,7 None of the patients in the present study
had such low levels of JAK2 V617F alleles. However, it is
interesting that patient no. 2 with 21% JAK2 V617F alleles in PB
is the only patient in this series with a significantly larger JAK2
mutant burden in BM. This may be an indication that patients
with low levels of detectable JAK2 V617F allele burden in PB
may have harbored a significantly larger mutant burden in BM.
Future studies of ‘low-burden’ JAK2 V617F-positive patients
could elucidate a theoretical model of increasing propensity of
the mutant cells to egress from the BM as the mutant burden in
BM increases, as it is observed with CD34-positive cells in IMF.
In this study, we have demonstrated that the levels of the JAK2
V617F alleles in PB and BM is equivalent, at least in patients
with a mutant clone in PB accounting for more than 30%. The
quantification of the JAK2 V617F mutant clone in PB unfractio-
nized WBCs is an exact and reliable determinant of disease
burden at diagnosis. As the clonal involvement of various
mature hematopoietic cells is very heterogenous and varies
between patients, and a separation of, for example, granulocytes
is sometimes difficult because of in vivo and in vitro aggregation
of monocytes, granulocytes and platelets,8 the use of unfrac-
tionized WBC as DNA source seems rational. Hereby the time-
to-time uncertainty and potential bias from an unsuccessful
separation procedure are eliminated. A prospective trial
elucidating the dynamics of the JAK2 V617F clone with serial
measurements of the JAK2 V617F allele burden in both PB
and BM during ongoing cytoreductive therapy with, for
example, hydroxyurea, interferon-a or a future JAK2 inhibitor is
warranted.
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Studies of cell lineage involvement and of cell origin in acute
myeloid leukaemia with normal karyotype (AML-NK) have
traditionally been hampered by the lack of clonality markers.
Recently, we identified NPM1 mutations as the most common
genetic alteration occurring in AML-NK (50–60% of cases).1,2
NPM1 mutations represent an ideal genetic lesion for tracking
cell lineage involvement in AML, as they are usually expressed
in all leukaemic cells1 and are very stable.2 More importantly,
NPM1 mutations generate NPM mutated proteins which are
aberrantly expressed in the cytoplasm of leukaemic cells.3 Thus,
NPM cytoplasmic positivity (NPMcþ ) represents a unique tool
for studying by immunohistochemistry cell lineage involve-
ment4 in fixed paraffin-embedded bone marrow samples from
NPMcþ AML patients.
Combining immunohistochemistry with analysis of NPM1
mutations on laser-microdissected haemopoietic cells, we found
involvement of two or more myeloid lineages in a large
proportion of NPMcþ AML.4 However, whether lymphoid
lineages are also involved in NPMcþ AML still remains an open
question. Immunohistochemical analysis of reactive lymphoid
nodules in bone marrow biopsies from three NPMcþ AML
patients did not reveal aberrant cytoplasmic dislocation of
NPM,4 suggesting that lymphoid cells are not targeted by NPM1
mutations. However, reactive lymphoid nodules may not be
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